Intellia Therapeutics Inc (NTLA)

In the last 90 days, Intellia Therapeutics Inc. reported one insider trading transaction, which involved a planned sale by insider Muna Bhanji on April 29, 2025, totaling $2,252.50 for 265 shares. This transaction reflects a net selling activity, with no net buying from insiders during this period. The company experienced a 10.1% increase in stock price over the same timeframe, and its last earnings report indicated a 13.46% earnings per share beat.

Track

Stock chart
Ticker: NTLA Exchange: NMS


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Earnings
 
Value bought

Past 90 days

 
Value sold

Past 90 days

 
Net insiders buying

Past 90 days

 
Trades (buy and sell)

Past 90 days

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-01 2025-04-29 PS Planned sale

Bhanji Muna

Non-Executive Director
265 -1.4%
8.50
USD 2,253 		265 -1.4% 8.50 USD 2,253
2025-03-04 2025-03-04 S Sale

Clark Eliana

EVP, Chief Technical Officer

Officer
679 -0.7%
8.99
USD 6,104 		679 -0.7% 8.99 USD 6,104
2025-03-04 2025-03-04 S Sale

BASTA JAMES

EVP, General Counsel

Officer
2,572 -2.2%
8.99
USD 23,122 		2,572 -2.2% 8.99 USD 23,122
2025-01-31 2025-01-29 PS Planned sale

Bhanji Muna

Non-Executive Director
265 -1.3%
9.97
USD 2,642 		265 -1.3% 9.97 USD 2,642
2025-01-07 2025-01-03 S Sale

Dube Michael P

VP, Chief Accounting Officer

Officer
1,372 -2.9%
12.18
USD 16,711 		1,372 -2.9% 12.18 USD 16,711
2025-01-07 2025-01-03 S Sale

Hicks Derek

EVP, Chief Business Officer

Officer
6,502 -9.8%
12.18
USD 79,194 		6,502 -9.8% 12.18 USD 79,194
2025-01-07 2025-01-03 S Sale

LEONARD JOHN M

President and CEO

Executive Director
26,807 -2.8%
12.18
USD 326,509 		26,807 -2.8% 12.18 USD 326,509
2025-01-07 2025-01-03 S Sale

BASTA JAMES

EVP, General Counsel

Officer
7,074 -8.7%
12.18
USD 86,161 		7,074 -8.7% 12.18 USD 86,161
2025-01-07 2025-01-03 S Sale

Lebwohl David

EVP, Chief Medical Officer

Officer
9,557 -9.8%
12.18
USD 116,404 		9,557 -9.8% 12.18 USD 116,404
2025-01-07 2025-01-03 S Sale

Sepp-Lorenzino Laura

EVP, Chief Scientific Officer

Officer
8,966 -10.4%
12.18
USD 109,206 		8,966 -10.4% 12.18 USD 109,206
2025-01-06 2025-01-03 S Sale

Clark Eliana

EVP, Chief Technical Officer

Officer
7,422 -10.4%
12.18
USD 90,400 		7,422 -10.4% 12.18 USD 90,400
2025-01-06 2025-01-02 PS Planned sale

Clark Eliana

EVP, Chief Technical Officer

Officer
556 -0.8%
12.03
USD 6,689 		556 -0.8% 12.03 USD 6,689
2024-10-04 2024-10-02 S Sale

Dube Michael P

VP, Chief Accounting Officer

Officer
2,012 -4.1%
19.01
USD 38,248 		2,012 -4.1% 19.01 USD 38,248
2024-07-03 2024-07-01 PS Planned sale

Clark Eliana

EVP, Chief Technical Officer

Officer
405 -0.6%
22.93
USD 9,287 		405 -0.6% 22.93 USD 9,287
2024-06-20 2024-06-17 PS Planned sale

Verwiel Frank

Non-Executive Director
1,505 -7.7%
25.00
USD 37,625 		1,505 -7.7% 25.00 USD 37,625
2024-03-05 2024-03-04 S Sale

BASTA JAMES

EVP, General Counsel

Officer
2,297 -2.7%
32.99
USD 75,778 		2,297 -2.7% 32.99 USD 75,778
2024-03-05 2024-03-04 S Sale

Clark Eliana

EVP, Chief Technical Officer

Officer
605 -0.8%
32.99
USD 19,959 		605 -0.8% 32.99 USD 19,959
2024-01-10 2024-01-08 PS Planned sale

Sepp-Lorenzino Laura

EVP, Chief Scientific Officer

Officer
667 -1.5%
29.38
USD 19,596 		667 -1.5% 29.38 USD 19,596
2024-01-10 2024-01-08 PS Planned sale

Sepp-Lorenzino Laura

EVP, Chief Scientific Officer

Officer
1,608 -3.5%
28.66
USD 46,085 		1,608 -3.5% 28.66 USD 46,085
2024-01-05 2024-01-03 S Sale

Goddard Glenn

EVP, Chief Financial Officer

Officer
5,365 -11.7%
29.46
USD 158,053 		5,365 -11.7% 29.46 USD 158,053
// ... existing code ...